Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) and Pluri (NASDAQ:PLUR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability.
Institutional & Insider Ownership
66.0% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 6.2% of Lyell Immunopharma shares are owned by insiders. Comparatively, 43.2% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Lyell Immunopharma and Pluri”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lyell Immunopharma | $40,000.00 | 8,403.63 | -$274.45 million | ($12.56) | -1.09 |
| Pluri | $1.02 million | 13.82 | -$23.82 million | ($2.65) | -0.37 |
Pluri has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Lyell Immunopharma has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500. Comparatively, Pluri has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and recommmendations for Lyell Immunopharma and Pluri, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lyell Immunopharma | 1 | 1 | 6 | 1 | 2.78 |
| Pluri | 1 | 0 | 0 | 0 | 1.00 |
Lyell Immunopharma presently has a consensus target price of $40.00, indicating a potential upside of 192.61%. Given Lyell Immunopharma’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Lyell Immunopharma is more favorable than Pluri.
Profitability
This table compares Lyell Immunopharma and Pluri’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lyell Immunopharma | -1,701,066.75% | -107.62% | -80.01% |
| Pluri | -1,943.87% | N/A | -106.56% |
Summary
Pluri beats Lyell Immunopharma on 8 of the 15 factors compared between the two stocks.
About Lyell Immunopharma
Lyell Immunopharma is a clinical-stage biotechnology company developing engineered T-cell therapies for people with cancer, with a focus on solid tumors. Its research aims to improve T cells’ ability to recognize and attack cancer cells and to remain active in the challenging environment inside tumors. The company’s investigational programs have included CAR T-cell and tumor-infiltrating lymphocyte (TIL) therapies. These approaches use a patient’s own immune cells, which are modified or selected and expanded before being administered as a potential treatment.
About Pluri
Pluri Ltd. is an Israel-based biotechnology company developing cell-based products and technologies. Its therapeutic research centers on PLX cells, derived from human placental tissue and expanded using the company’s cell-manufacturing platform. Pluri has investigated these cells for potential use in a range of medical conditions; its therapies remain in development. The company also applies its cell-expansion technology to areas beyond medicine, including food technology and agriculture, where it is exploring cell-based products and production methods.
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.
